19,054 Shares in Bristol-Myers Squibb Co (NYSE:BMY) Purchased by ARP Americas LP

ARP Americas LP acquired a new stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 19,054 shares of the biopharmaceutical company’s stock, valued at approximately $1,120,000. Bristol-Myers Squibb comprises about 0.1% of ARP Americas LP’s investment portfolio, making the stock its 23rd biggest position.

A number of other hedge funds have also recently made changes to their positions in BMY. JCIC Asset Management Inc. purchased a new stake in Bristol-Myers Squibb during the 1st quarter valued at about $25,000. Perennial Advisors LLC purchased a new stake in Bristol-Myers Squibb during the 1st quarter valued at about $27,000. CVA Family Office LLC purchased a new stake in Bristol-Myers Squibb during the 1st quarter valued at about $28,000. MBE Wealth Management LLC purchased a new stake in Bristol-Myers Squibb during the 1st quarter valued at about $41,000. Finally, AlphaCore Capital LLC purchased a new stake in Bristol-Myers Squibb during the 1st quarter valued at about $49,000. 74.20% of the stock is currently owned by institutional investors.

In other news, Director Dinesh C. Paliwal bought 9,174 shares of the firm’s stock in a transaction on Monday, June 15th. The shares were bought at an average price of $54.50 per share, for a total transaction of $499,983.00. Following the purchase, the director now owns 22,109 shares in the company, valued at $1,204,940.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Louis S. Schmukler sold 25,000 shares of the firm’s stock in a transaction that occurred on Tuesday, May 19th. The stock was sold at an average price of $62.68, for a total transaction of $1,567,000.00. Following the sale, the executive vice president now owns 26,777 shares in the company, valued at approximately $1,678,382.36. The disclosure for this sale can be found here. 0.14% of the stock is currently owned by company insiders.

Several analysts recently commented on BMY shares. Seaport Global Securities started coverage on shares of Bristol-Myers Squibb in a research report on Tuesday. They set an “outperform” rating and a $75.00 price objective on the stock. Cantor Fitzgerald raised their price target on shares of Bristol-Myers Squibb from $68.00 to $88.00 in a report on Tuesday, June 2nd. William Blair reaffirmed a “buy” rating on shares of Bristol-Myers Squibb in a report on Monday, June 1st. ValuEngine downgraded shares of Bristol-Myers Squibb from a “sell” rating to a “strong sell” rating in a report on Monday, June 1st. Finally, Zacks Investment Research downgraded shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $66.00 price target on the stock. in a report on Thursday, April 16th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and thirteen have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $68.93.

Shares of BMY traded down $0.21 on Friday, reaching $58.66. The company’s stock had a trading volume of 10,439,919 shares, compared to its average volume of 9,155,796. The company has a debt-to-equity ratio of 0.86, a current ratio of 1.66 and a quick ratio of 1.51. The stock has a market capitalization of $132.73 billion, a P/E ratio of 72.42, a PEG ratio of 1.12 and a beta of 0.73. The stock’s 50 day simple moving average is $58.18 and its two-hundred day simple moving average is $60.16. Bristol-Myers Squibb Co has a 12-month low of $44.00 and a 12-month high of $68.34.

Bristol-Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.49 by $0.23. Bristol-Myers Squibb had a net margin of 3.08% and a return on equity of 30.06%. The company had revenue of $10.78 billion for the quarter, compared to the consensus estimate of $10.04 billion. During the same quarter last year, the firm posted $1.10 earnings per share. The firm’s revenue was up 82.1% compared to the same quarter last year. Analysts expect that Bristol-Myers Squibb Co will post 6.18 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Monday, July 6th will be paid a dividend of $0.45 per share. This represents a $1.80 dividend on an annualized basis and a yield of 3.07%. The ex-dividend date is Thursday, July 2nd. Bristol-Myers Squibb’s payout ratio is 38.38%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.

See Also: What is Green Investing?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.